Company intelligence / Profile preview

Vivacelle Bio

Kansas City, Missouri, United Statesvivacellebio.com ↗
Ownership
Private
Employees
~10
Development stage
Other
01

Overview

Vivacelle Bio’s lead asset, VBI-S, has entered a Phase 3 trial targeting patients with hypovolemia due to septic shock who have failed standard therapies. The product demonstrated strong efficacy in a Phase II trial—100% of treated patients achieved elevated blood pressure and improved organ function when refractory to standard care. The company’s technology addresses both absolute and relative hypovolemia by restoring intravascular volume and redistributing nitric oxide. Preclinical data for the earlier-stage product, VBI‑1, suggest it may be two-to-three times more effective than current standards in animal models.

Therapeutic areas
CardiovascularInfectious Diseases
Modalities
Phospholipid nanoparticles (novel resuscitation fluids)Small molecule drugs (as per pipeline classification)
Industry
Biotech
02

Drug pipeline

2 assets

VBI-S

3

1 more asset in the full pipeline.

03

Partnerships

U.S. Department of Defense/Naval Medical Research Command via MTEC funding for clinical trialsNational Institutes of Health support

Beyond the preview

Go deeper on Vivacelle Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivacelle Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call